Longer recurrence-free survival in a patient with metastatic renal cell carcinoma treated with temsirolimus

Temsirolimus did not demonstrate an efficacy advantage compared with sorafenib as second-line therapy in patients with metastatic renal cell carcinoma (mRCC). Only a few patients achieved complete responses, and the median progression-free survival rate remains short. We report one patient with mRCC...

Full description

Saved in:
Bibliographic Details
Published in:Clinical case reports 2017, Vol.5 (12), p.1950-1953
Main Authors: Satoh, Tendo, Koie, Takuya, Horiguchi, Hirotaka, Tokui, Noriko, Narita, Satoshi, Ohyama, Chikara
Format: Report
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Temsirolimus did not demonstrate an efficacy advantage compared with sorafenib as second-line therapy in patients with metastatic renal cell carcinoma (mRCC). Only a few patients achieved complete responses, and the median progression-free survival rate remains short. We report one patient with mRCC who had a continuing response to temsirolimus.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.1181